Puma Biotechnology (PBYI) EBIT Growth (3y) (2013 - 2026)
Powered by 
Analysis
Puma Biotechnology (PBYI) EBIT Growth (3y) (2013 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 6.70% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 8.36% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 89.72% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 24.14% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 44.54% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 44.34% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | -18.82% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 81.27% |
| 10 | Puma Biotechnology | 486.99 Mn | 393.08 Mn | 44.03 Mn | 15.74% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 15.74% |
| Mar 31, 2026 | -42.23% |
| Dec 31, 2025 | 19.53% |
| Sep 30, 2025 | 58.75% |
| Jun 30, 2025 | -18.05% |
| Mar 31, 2025 | 94.28% |
| Dec 31, 2024 | 25.07% |
| Sep 30, 2024 | 64.68% |
| Jun 30, 2024 | 49.21% |
| Mar 31, 2024 | -28.34% |
| Dec 31, 2023 | 49.29% |
| Sep 30, 2023 | 39.38% |
| Jun 30, 2023 | -11.80% |
| Mar 31, 2023 | 32.12% |
| Dec 31, 2022 | 46.68% |
| Sep 30, 2022 | 29.38% |
| Jun 30, 2022 | 35.13% |
| Mar 31, 2022 | -27.57% |
| Dec 31, 2021 | 33.30% |
| Sep 30, 2021 | 7.41% |